Celecoxib API Market Size was valued at USD 58.9 Mn in 2023 and is predicted to reach USD 87.0 Mn by 2031 at a 5.1% CAGR during the forecast period for 2024-2031.
Celecoxib API marketing focuses on the production, distribution, and retail sale of celecoxib as a component in various pharmaceutical products. In addition to relieving inflammation and pain, nonsteroidal anti-inflammatory medications such as celecoxib can also lower body temperature. The rising demand for celecoxib API in pharmaceutical and laboratory applications worldwide is driving the market's expansion. The research delves into the profitable prospects in the celecoxib API market. Furthermore, the global celecoxib API market is experiencing strong growth due to numerous key factors, such as reduced inflammation and pain; there is an increasing demand for high-quality active pharmaceutical components like celecoxib. There has been a lot of investment from pharmaceutical companies in developing effective therapies for conditions like arthritis, which has led to a strong demand for celecoxib. Sustainable and ecologically friendly production practices are also becoming more important in the global celecoxib API market.
However, the market growth needs to be improved by a complex regulatory landscape encompassing pharmaceutical manufacture, necessitating extensive testing, quality assurance, and compliance paperwork, resulting in heightened production expenses and delays in product launch, which slows down the celecoxib API market growth. In addition, the celecoxib API market is being significantly influenced by research in pharmaceutical production and technical improvements. In order to create celecoxib with a high level of purity, manufacturers and researchers are putting money into state-of-the-art technology and new methods, providing opportunities for market growth in the coming years.
Competitive Landscape
Some of the Major Key Players in the Celecoxib API Market are
- Pfizer
- Teva Pharmaceuticals
- Viatris
- ScinoPharm
- Jiangxi Synergy
- Jiangsu Hengrui Medicine
- Jiangsu Chiatai Qingjiang
- Hisun Pharmaceutical Nantong
- Aurobindo Pharma
- Punjab Chemicals
- Other Prominent Players
Market Segmentation:
The celecoxib API market is segmented based on type and application. Based on type, the market is segmented into standard-grade celecoxib API and micronized celecoxib API. By application, the market is segmented into pharmaceutical and laboratory.
Based on the Type, the Standard Grade Celecoxib API Segment is Accounted as a Major Contributor to the Celecoxib API Market
The standard-grade celecoxib API celecoxib API market is expected to hold a major global market share in 2023. This is propelled by the demonstrated safety and efficaciousness in the management of various ailments, including pain and arthritis. Celecoxib active pharmaceutical ingredient manufacture and distribution are subject to stringent requirements because of the strong regulatory frameworks. Furthermore, rheumatoid arthritis and osteoarthritis, two chronic inflammatory disorders, are becoming more common worldwide, particularly among the elderly. The need for standard-grade celecoxib API is being driven up by the growing need for safe and effective anti-inflammatory drugs, which is being driven up by this demographic trend, fueling the expansion of the market.
Pharmaceutical Segment to Witness Growth at a Rapid Rate
The pharmaceutical industry is growing because chronic inflammatory illnesses are becoming more common. In addition, this market segment is growing at a rapid pace due to the global aging population. Moreover, the pharmaceutical section of the celecoxib API market is expected to rise due to continuing research and development efforts that are investigating potential new therapeutic uses of celecoxib in different medical conditions.
In the Region, the North American Celecoxib API Market Holds a Significant Revenue Share
The North American celecoxib API market is expected to register the highest market share in revenue in the near future. It can be attributed to the high prevalence of arthritis and other chronic pain-related ailments in the region, which necessitates the development of effective drugs to manage inflammation and an older population that is more prone to these illnesses. In addition, Asia Pacific is projected to grow rapidly in the global celecoxib API market because of a highly developed healthcare system, substantial healthcare spending, a thriving pharmaceutical industry, generic medication makers, and a strict regulatory environment.
Recent Developments:
- In April 2024, Pfizer Inc. revealed excellent top-line immunogenicity and safety findings from the current pivotal Phase 3 clinical trial called MONeT (RSV IMmunizatiON Study for AdulTs at Higher Risk of Severe Illness). In people 18 to 59 years old who were at risk of developing severe respiratory syncytial virus-associated lower respiratory tract disease, a single dosage of ABRYSVO was compared with a placebo in this experiment.
- In January 2024, Teva announced that it would be selling its business related to active pharmaceutical ingredients (APIs). TAPI, a global leader in the small-molecule API market, employs about 4,300 people.
Celecoxib API Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 58.9 Mn |
|
Revenue Forecast In 2031 |
USD 87.0 Mn |
|
Growth Rate CAGR |
CAGR of 5.1% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, By Application and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Pfizer, Teva Pharmaceuticals, Viatris, ScinoPharm, Jiangxi Synergy, Jiangsu Hengrui Medicine, Jiangsu Chiatai Qingjiang, Hisun Pharmaceutical Nantong, Aurobindo Pharma, and Punjab Chemicals. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
